M. V. Cunha is a long-term investor and founder of MVC Investing, specializing in equity analysis with a focus on fundamental analysis and valuation. He holds a BSc in Economics and an MSc in Finance, and has been actively investing since early 2020, developing a concentrated portfolio strategy centered on high-conviction small-cap stocks.
No chart yet. A chart needs 8 resolved predictions, and M. has 4. The predictions themselves are below.
SORT
STILL OPEN
?
If in 2025 they converted 40% of incremental revenue into EBITDA, it’s hard to believe adj. EBITDA margins will only move from 2.5% to 3.5% in 2026.
Due Dec 31, 2026March 6, 2026FinanceEarningsPending
—
SCORE
?
Omada will have a strong start to 2027.
Due Mar 31, 2027August 8, 2026FinanceGrowthPending
—
SCORE
?
$OMDA could 5x from here
Due Oct 31, 2027October 2026stocksinvestmentPending
—
SCORE
?
Sign in to read this call.
own side · their own organization · shown, counts only if it does not happen
Due Dec 31, 2027December 11, 2025FinanceInvestingPending
—
SCORE
?
Current analyst estimates for 2028 EBITDA imply an adjusted EBITDA margin of ~6%, but based on my expectations it will likely be closer to 15%+.
Due Dec 31, 2028March 6, 2026FinanceEarningsPending
—
SCORE
?
Sign in to read this call.
Due Dec 31, 2028February 28, 2026pharmaceuticalproduct developmentPending
—
SCORE
?
Omada will not return to a negative bottom line from here.
August 8, 2026FinanceProfitabilityPending
—
SCORE
?
I expect expansions in the UK and Israel, and I wouldn’t be surprised to see a new data center built from scratch in Paris, France.
May 6, 2026ExpansionData CenterPending
—
SCORE
?
Sign in to read this call.
February 28, 2026pharmaceuticalinvestmentPending
—
SCORE
?
Sign in to read this call.
February 28, 2026pharmaceuticalproduct launchPending
—
SCORE
RESOLVED · NEWEST FIRST
◇
Omada will beat and raise guidance again next quarter.
August 8, 2026FinanceEarningsNo verdict
—
SCORE
✓
Nebius is set up for a clear revenue beat.
May 6, 2026call #3EarningsRevenueCorrect
30
SCORE
◇
I expect to see at least two or three new locations discussed in the upcoming report.
May 6, 2026CapacityExpansionToo vague to check
—
SCORE
✓
I would be surprised if we don’t see at least the two colocation sites announced this quarter.
May 6, 2026call #4CapacityColocationCorrect
97
SCORE
✓
Sign in to read this call.
November 9, 2025call #1EarningsNBISCorrect
30
SCORE
✓
Sign in to read this call.
November 9, 2025call #2EarningsPGYCorrect
63
SCORE
Still open · 10
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
If in 2025 they converted 40% of incremental revenue into EBITDA, it’s hard to believe adj. EBITDA margins will only move from 2.5% to 3.5% in 2026.
Due Dec 31, 2026Said March 6, 2026FinanceEarnings
?No market prices this claim
Omada will have a strong start to 2027.
Due Mar 31, 2027Said August 8, 2026FinanceGrowth
?No market prices this claim
$OMDA could 5x from here
Due Oct 31, 2027Said October 2026stocksinvestment
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2027Said December 11, 2025FinanceInvesting
?No market prices this claim
Current analyst estimates for 2028 EBITDA imply an adjusted EBITDA margin of ~6%, but based on my expectations it will likely be closer to 15%+.
Due Dec 31, 2028Said March 6, 2026FinanceEarnings
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2028Said February 28, 2026pharmaceuticalproduct development
?No market prices this claim
Omada will not return to a negative bottom line from here.
Said August 8, 2026FinanceProfitability
?No market prices this claim
I expect expansions in the UK and Israel, and I wouldn’t be surprised to see a new data center built from scratch in Paris, France.
Said May 6, 2026ExpansionData Center
?No market prices this claim
Sign in to read this call.
Said February 28, 2026pharmaceuticalinvestment
?No market prices this claim
Sign in to read this call.
Said February 28, 2026pharmaceuticalproduct launch